OSHLACK, BENJAMIN,CHASIN, MARK,MINOGUE, JOHN JOSEPH,KAIKO, ROBERT FRANCIS
申请号：
HU0401532
公开号：
HU227815B1
申请日:
1992.11.25
申请国别(地区):
HU
年份:
2012
代理人:
摘要：
(A) Controlled release oxycodone formulation for oral admin. to human patients, comprises (i) 10-40mg oxycodone or its salt, the formulation providing a mean max. plasma conc. of oxycodone of 6-60 ng/ml from a mean of 2-4.5 hrs.. After admin., and a mean min. plasma conc. of 3-30 ng/ml from a mean of 10-14 hrs. after repeated admin. every 12 hrs. through steady state conditions. (ii) 10-160 mg oxycodone or its salt, the formulation providing a mean max. plasma conc. of oxycodone of 6-240 ng/ml from a mean of 2-4.5 hrs. after admin., and a mean min. plasma conc. from 3-120 ng/ml from a mean of 10-14 hrs. after repeated admin. every 12 hrs. through steady-state conditions. (B) Also claimed is a solid controlled release oral dosage form comprising (i) oxycodone or its salt in amt. of 10-160 mg； a controlled release matrix selected from hydrophilic hydrophobic polymers, digestible opt. substd. 8-50C hydrocarbons, and/or polyalkylene glycols； and a diluent； wherein the compsn. provides a mean max. plasma conc. of oxycodone of 6-240 ng/ml from a mean of 2-4.5 hrs. after admin, and mean min. plasma conc. of 3-120 ng/ml from a mean of 10-14 hrs. after repeated admin. every 12 hrs. through steady-state conditions； or (ii) an analgesically effective amt. of spheroids comprising oxycodone or its salt and either a spheronising agent or an acrylic polymer or copolymer, such that the total dosage of oxycodone in the dosage form is 10-160 mg； a film coating which controls the release of the oxycodone or its salt at a controlled rate in an aq. medium, wherein the compsn. provides an in vitro dissolution rate of the dosage form.
